OTC “dividends” are not uncommon at all. Usually (worthless) stock based or some token cash value. I can think of half a dozen without breaking a sweat.
The “dividend” narrative is about the story and whether it can sell stock and increase the price. This is usually of far greater value than the dividend itself ever is....which is why you see it in pennyland.
And the VYST PR even goes so far to say that the intent is to sell stock....lol.
“....and attract new shareholders who will buy Vystar shares to reap the dividend.“
But it appears the market isn’t buying into the hype....
Exactly Shatts! And it's not just a dividend play anyways right! It's a spin off dividend play directly tied to unlocking just 1 of VYST's stable of proprietary commercialization products, which as you point out is definitely rare in the OTC.
And kudos to VYST's BOD's for even finding such a brilliant creative way to unlock the inherent value in their UV400 units!
As no-one saw such a creative commercialization era deal coming period.
And I can't wait to see the major healthcare manufacturer revealed directly ahead. Because I already know it's going to hit this stock like a THUNDERBOLT, because it will prove that VYST's begun successfully transitioning final stage trials/talks into commercial scale partnerships with relevant BIG FISH partners of consequence!
My only real question right now is just how many more behind the scenes talks/trials is VYST preparing to successfully transition into creative commercial scale partnerships now through end of year alone...as the snowball effect and guessing game of additional commercialization era partners coming will definitely begin simultaneous with CEO Rotman delivering the healthcare manufacturer referenced yesterday and the Rotmans Super 8k! And logic strongly suggests both will be arriving over these next couple of weeks now that CEO Rotman's finally ready to hit the ground running after several months of preparation!
News 
Market Data 
Discover 
